KALY – Kali-Extracts, Inc. Publishes Cannabis Extract Lung Disease Treatment Study Preview
DALLAS, Feb. 05, 2019 (GLOBE NEWSWIRE) -- via OTC
PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.)
(KALY) (“KALYâ€) today published a preview
of the recently announced long-term, pilot study on the treatment
of Chronic Obstructive Pulmonary Disease (COPD) in primates
with cannabis extracts derived from Kali-Extracts patented cannabis
extraction process. The study adds to the Kali-Extracts in
vitro genomics study, previously announced, to evaluate the impact
of its pharmaceutical grade cannabis extracts in combination with
other therapies on COPD patients. The World Health
Organization estimates 65 million people worldwide are afflicted
with moderate to severe COPD and GlobalData forecasts that the COPD
treatment market will reach $14.1 billion by 2025.
The primate study was conducted by Professor
Jeffry Osbourn, Ph.D., from the University of Kentucky and his
Biomedical Science Research Group (BSRG). Professor Osbourn
made the following statement in regard to the research: “We
investigated the effects of a novel, new oral-delivered agent for
the treatment of lung diseases like asthma, and inflammation of the
lung airways, in research animals. To our surprise, the new
[Kali-Extracts] supplement increased lung capacity by 2 to 3 times
and increased the rate of breathing, returning lung function to
normal. These large increases in lung function would likely
lead to improved oxygen levels in the blood and increased breathing
ability in these animals. Future experiments are planned to
more closely identify the mechanisms of this improved overall lung
function leading to greatly improved life styles and greater
participation in daily activities for these patients.â€
A final report on the primate study is coming in
March.
Kali-Extracts, Inc. (“KALYâ€) is a health and
wellness company set to generate revenue from its patented cannabis
extraction technology through overlapping go-to-market
strategies. KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. Similarly, KALY its patented cannabis
extraction technology to develop pharmaceutical products internally
and through partnerships.
KALY has licensed its extraction process to
Puration, Inc. (PURA) (“PURAâ€) for the
production of beverages. With over $1 million in trailing
twelve-month sales, PURA’s sales of EVERx CBD Sports Water are
growing. KALY is now working with PURA to formulate a 25 MG
CBD formula for a new CBD infused water product. Together,
PURA and KALY have signed over a $1 million agreement to produce
CBD infused water for Generex Biotechnology, Inc. (GNBT). The GNBT product is expected to be on
shelves soon. The PURA and KALY agreement with GNBT is part
of a larger agreement to explore potential pharmaceutical
partnerships.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), and as such, may involve
risks and uncertainties. These forward looking statements relate
to, amongst other things, current expectation of the business
environment in which the company operates, potential future
performance, projections of future performance and the perceived
opportunities in the market. The company's actual performance,
results and achievements may differ materially from the expressed
or implied in such forward-looking statements as a result of a wide
range of factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459
